Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT study of sparsentan versus irbesartan in IgA nephropathy
ACTRN12618001511224Phase 3Not yet recruiting
- Sponsor
- Travere Therapeutics
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of sparsentan and irbesartan in IgA nephropathy (IgAN), sponsored by Travere Therapeutics. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
sparsentanirbesartan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ACTRN12618001511224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001511224.